TB Research

Ionophoric effects of the antitubercular drug bedaquiline

Hards K, McMillan DGG, Schurig-Briccio LA, Gennis RB, Lill H, Bald D, Cook GM

Proceedings of the National Academy of Sciences of the United States of America · 2018-06

Abstract

Bedaquiline (BDQ), an inhibitor of the mycobacterial F 1 F o -ATP synthase, has revolutionized the antitubercular drug discovery program by defining energy metabolism as a potent new target space. Several studies have recently suggested that BDQ ultimately causes mycobacterial cell death through a phenomenon known as uncoupling. The biochemical basis underlying this, in BDQ, is unresolved and may represent a new pathway to the development of effective therapeutics. In this communication, we demonstrate that BDQ can inhibit ATP synthesis in Escherichia coli by functioning as a H + /K + ionophore, causing transmembrane pH and potassium gradients to be equilibrated. Despite the apparent lack of a BDQ-binding site, incorporating the E. coli F o subunit into liposomes enhanced the ionophoric activity of BDQ. We discuss the possibility that localization of BDQ at F 1 F o -ATP synthases enables BDQ to create an uncoupled microenvironment, by antiporting H + /K + Ionophoric properties may be desirable in high-affinity antimicrobials targeting integral membrane proteins.

MeSH terms

  • Escherichia coli
  • Proton-Translocating ATPases
  • Escherichia coli Proteins
  • Adenosine Triphosphate
  • Ionophores
  • Antitubercular Agents
  • Hydrogen-Ion Concentration
  • Diarylquinolines